Open House Originale Rabattverträge 2025-13 - Fluticason, Umeclidinium, Vilanterol (Wirkstoffkombination)
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-13 - Fluticason, Umeclidinium, Vilanterol (Wirkstoffkombination)
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
25 / 100
Risk factors
If the patent or market exclusivity expires before the contract end, the contract terminates automatically at the end o...
Submission is only possible via email (with QES) or postal mail. No electronic submission via portal.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until May 2027
- Conclusion of discount agreements (Rabattverträge) under § 130c SGB V for the supply of Fluticason, Umeclidinium, Vilanterol combination products.
- Agreements are open to all qualified pharmaceutical entrepreneurs on uniform terms.
Show full summary
Techniker Krankenkasse (TK) and other health insurances (HEK, hkk) are offering open house discount agreements for the drug combination Fluticason, Umeclidinium, Vilanterol. Any eligible pharmaceutical entrepreneur can join under uniform conditions with no exclusivity. The contract runs for a maximum of 24 months until 31 May 2027. No estimated value is provided.
Risks
If the patent or market exclusivity expires before the contract end, the contract terminates automatically at the end o...
Submission is only possible via email (with QES) or postal mail. No electronic submission via portal.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.
- Must have a valid marketing authorization for the specific medicinal product combination in Germany.
Administrative
- Must submit a self-declaration (Eigenerklärung) regarding authorization and reliability (Anlage 4 zum Vertrag).
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Originale Rabattverträge 2025-13 - Fluticason, Umeclidinium, Vilanterol (Wirkstoffkombination)
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Fluticason, Umeclidinium, Vilanterol zu schließen.
Location
Duration
Category
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Fluticason, Umeclidinium, Vilanterol zu schließen.
Value note
Procurement Details
- Publication date
- 16 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 252511-2025
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
25 / 100
Risk factors
If the patent or market exclusivity expires before the contract end, the contract terminates automatically at the end o...
Submission is only possible via email (with QES) or postal mail. No electronic submission via portal.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications